Duke logo

UM1 10136 AZD1775 in Patients with CCNE1 Amplification - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drug AZD1775 is safe and can help control the disease in patients with advanced cancer with changes in Cyclin E1 gene.

What is the Condition Being Studied?

Advanced cancer with a change in the gene called the CCNE1 (Cyclin E1) gene

Who Can Participate in the Study?

Adults with advanced cancer with a change in the gene called the CCNE1 (Cyclin E1) gene who:
- Have not had radiation treatment within 7 days of starting the study drug
- Are able to swallow pills
- Have biopsy tissue available or will agree to study biopsies

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Take the study drug AZD1775 by mouth once daily for five days during the first and second week of each 3-week cycle.

Study Details

Full Title
A Phase II Study of AZD1775, a WEE1 Inhibitor, in Patients with CCNE1 Amplification (10136)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00101068
NCT:NCT03253679
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698